Trial Profile
Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Praziquantel (Primary)
- Indications Schistosomiasis
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 29 Nov 2018 Status changed from recruiting to completed.
- 17 Sep 2018 Planned End Date changed from 30 Jan 2019 to 21 Nov 2018.
- 03 May 2018 Planned End Date changed from 26 Sep 2018 to 30 Jan 2019.